Journal of Exploratory Research in Pharmacology
August 28, 2023
Ryan Dao, Amit Aggarwal
2 citations
Major depressive disorder (MDD) continues to be a prevalent disease worldwide. While selective serotonin reuptake inhibitors and other medications continue to be prescribed, further research has been conducted toward other treatment modalities. Within the past decade, ketamine, an N-methyl-d-aspartate receptor antagonist, has been extensively studied as a new treatment for MDD. Recent studies...
Psychiatry Research Case Reports
August 20, 2023
Brian S. Barnett, Amit Anand
Though usually mild, neuropsychiatric side effects of intravenous ketamine for depression occasionally result in treatment discontinuation. Two small clinical trials of healthy subjects have indicated that lamotrigine pre-treatment may attenuate these side effects, though two other trials, one in patients with unipolar depression and one in healthy male volunteers, did not support these...
Trials
August 19, 2023
Kaili Yu, Zhenguo Song, Bowen Zhang et al.
Pancreatoduodenectomy (PD) is traumatic, difficult to perform, and has a high incidence of postoperative complications and perioperative mortality. Postoperative complications and pain occur frequently and seriously affect the psychological status of patients. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic and antidepressant effects. In this study, we aim to...
Depression and Anxiety
August 19, 2023
Anna J. Harvey, Stevan Nikolin, Nicholas Chand et al.
4 citations
Ketamine has recently emerged as a highly effective new treatment for people with treatment-resistant depression with rapid antidepressant effects. However, these effects are often short lasting, and the potential cognitive mechanisms underlying the therapeutic effects, such as effects on emotional processing bias, remain poorly understood. In the present study, we explored potential changes in...
Trials
August 13, 2023
Irina Falkenberg, Florian Bitsch, Wei Liu et al.
4 citations
Abstract Background Major depressive disorder (MDD) is a highly prevalent (8–15%), severely disabling disorder and is associated with enormous socioeconomic impact. Antidepressant medication for the treatment of MDD has proven effective in RCTs; however, placebo response is also substantial. Given the potential benefits of modulating the placebo response in patient care and pharmacological...
BMC Psychiatry
August 11, 2023
Abstract: Background: Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II, remission rates were consistently higher among patients with MDD with active suicidality who...
Bipolar Disord
August 10, 2023
Renato de Filippis received travel grants and/or speaker/consultant fees from Janssen-Cilag. Pasquale De Fazio declares that the research was conducted without any commercial or financial relationship that could be construed as a potential conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1. Please...
CNS Drugs
August 9, 2023
Meredith Castro, Samuel T Wilkinson, Rayan K Al Jurdi et al.
Background: Treatment-resistant depression (TRD) is a chronic illness requiring long-term treatment. Esketamine nasal spray (ESK) has been studied in several long-term trials of patients with TRD, including SUSTAIN-1 (NCT02493868) and SUSTAIN-3 (NCT02782104). This subgroup analysis of SUSTAIN-3 evaluated patients with TRD who received a second induction (IND) and maintenance treatment with ESK...
Current Molecular Pharmacology
August 9, 2023
MIng Tatt Lee, Yu-Cheng Ho
2 citations
Keywords: Ketamine, depression, antidepressant, 2R6R-hydroxynorketamine, major depressive disorder, Spravato
Research Square
August 7, 2023
Rong Xu, Yiheng Pan, Maria Gorenflo et al.
preprint
Abstract Ketamine, including esketamine, is an effective treatment for patients with treatment-resistant depression (TRD); however, its long-term efficacy in real-world populations remains poorly characterized. This is a retrospective cohort study using TriNetX US Collaborative Network, a platform aggregating electronic health records (EHRs) data from 93 million patients from 56 health care...